MiNK Therapeutics, Inc. INKT

12.18 (0.12) (0.98%) as of 25 Sep
Market cap
$62.8M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
— — — — — — 0.00 —
P/S ratio
— — — — — — 0.00 —
P/FCF ratio
— — — — — — 0.00 —
P/Operating CF
— — — — — — (83.09) —
P/B ratio
— — — — — — 0.00 —
Price to Tangible BV
— — — — — — 0.00 —
EV/Sales
— — — — — — 0.00 —
EV/EBITDA
— — — — — — 0.00 —
EV/Operating CF
— — — — — — (25.97) —
EV/FCF
— — — — — — (25.47) —
Quick Ratio
1.03 0.66 0.30 1.55 2.36 0.19 0.04 —
Current Ratio
1.06 0.72 0.32 1.61 2.41 0.29 0.12 —
Net Debt/EBITDA
1.07 (0.03) 0.15 0.64 1.38 (2.82) (1.19) —
Debt/Assets
0.00% 86.08% 0.00% 0.00% 0.00% 962.07% 2,046.79% 0.00%
Debt/Equity
0.00 (0.25) 0.00 0.00 0.00 (0.81) (0.74) —
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 1.05 —
Operating CF/Net income
0.47 0.89 0.70 0.67 0.42 0.51 0.63 —
Capex/Depreciation
0.00 0.00 (0.36) (2.05) (3.19) (1.73) (11.59) —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
73.90% 57.30% 243.36% (239.49%) 200.76% 36.00% 52.77% —
ROA
(125.20%) (209.96%) (172.59%) (90.71%) (134.89%) (553.84%) (3,636.98%) —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% —
Return on Tangible Assets
(1,034.81%) 870.51% 327.84% (318.50%) (127.07%) 167.98% 389.56% —
Average Days of Receivables
— — — — 0.00 0.00 0.00 —
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,850.07% —
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 555.10% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.84% —
Graham Net Nets
— — — — — — (0.27) —
Graham Number
— — — — — — 0.00 —
Earnings Yield
— — — — — — (8.47%) —
Free Cash Flow Yield
— — — — — — (4.51%) —
Revenue per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.29 —
Operating CF per Share
(1.39) (2.53) (4.59) (5.60) (4.93) (3.46) (6.21) —
Capex per Share
0.00 0.00 (0.02) (0.07) (0.10) (0.04) (0.18) —
Free Cash Flow per Share
(1.39) (2.53) (4.61) (5.68) (5.02) (3.50) (6.39) —
Cash per Share
3.13 1.21 0.98 5.83 14.94 1.12 0.12 —
Shareholders Equity per Share
(3.33) (5.19) (5.25) (0.12) 9.14 (22.35) (15.10) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
(3.33) (5.19) (5.25) (0.12) 9.14 (22.35) (15.10) —
Free Cash Flow
(5.93) (9.56) (15.84) (19.12) (13.08) (8.43) (15.37) —
Working Capital
0.82 (1.97) (7.80) 7.72 23.17 (10.13) (6.50) —
Capital Expenditures
— — (0.07) (0.25) (0.25) (0.10) (0.43) —
Net Current Asset Value
(14.62) (20.32) (19.01) (1.47) 23.17 (54.33) (36.72) —
EV/EBIT
— — — — — — 0.00 —
Capex to Sales
— — 0.00 0.00 0.00 0.00 0.62 —
Net Profit Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (3,451.60%) —
Price to Operating Income
— — — — — — 0.00 —
Other line items
Depreciation/Fixed assets
0.46 0.29 0.21 0.11 0.13 0.12 0.09 —
Cash ROIC
728.16% 102.02% 113.81% (103.64%) (21.44%) 119.53% 165.88% —
Accounts Receivable Turnover
— — — — 0.00 0.00 1.77 —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Inventory Turnover
— — — 0.00 0.00 0.00 — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 — —
Average Receivables
— — — — 0.14 0.39 0.39 —
Average Payables
3.08 3.32 4.87 4.41 3.07 2.80 2.80 —
Average Assets
9.98 5.14 13.01 30.86 22.40 2.93 0.65 —
Average Common Equity
(16.91) (18.82) (9.23) 11.69 (15.05) (45.10) (45.10) —

Fold the line items

Columns are period end dates